The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?
- S. Y. Lim
- J. M. Horsman
- B. W. Hancock
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
- Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000034
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The Mantle Cell Lymphoma International Prognostic Index (MIPI) combines four factors to differentiate low-, intermediate- and high-risk prognostic groups in advanced mantle cell lymphoma using data from patients treated in clinical trials. To evaluate its use in routine practice, we applied the simplified index retrospectively to 50 consecutive new patients attending our lymphoma service. In the log-rank and multiple comparison statistical tests there was favorable differentiation between survival curves, and particularly between the high- and low-risk groups. We concluded that the MIPI is of value in routine lymphoma practice.